Epstein‐Barr virus‐specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma

201791 citationsJournal Articlebronze Open Access

Authors

Julian Huang · Harvard University

Mark H. Fogg · Brigham and Women's Hospital

Lori J. Wirth · Harvard University

Heather Daley · Harvard University

Jerome Ritz · Dana-Farber Cancer Institute

Marshall R. Posner · Harvard University

Fred C. Wang ·

Abstract

A durable response was observed with EBV-CTL immunotherapy, but the overall response rate for patients with recurrent, metastatic NPC was low. Further research is necessary to increase the efficacy of EBV-specific immunotherapy in patients with incurable NPC, and to characterize mechanisms for refacilitation to chemotherapy. Cancer 2017;123:2642-50. © 2017 American Cancer Society.

Topics & Keywords

Viral-associated cancers and disorders Polyomavirus and related diseases T-cell and Retrovirus Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 123, Issue 14, pp. 2642-2650

DOI: 10.1002/cncr.30541

Field-Weighted Citation Impact: 3.79